Free Trial

Short Interest in Roche Holding AG (OTCMKTS:RHHBY) Increases By 467.7%

Roche logo with Medical background
Remove Ads

Roche Holding AG (OTCMKTS:RHHBY - Get Free Report) saw a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 11,741,100 shares, a growth of 467.7% from the February 13th total of 2,068,200 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average trading volume of 9,269,800 shares, the short-interest ratio is presently 1.3 days.

Analyst Upgrades and Downgrades

RHHBY has been the subject of several research analyst reports. Sanford C. Bernstein upgraded shares of Roche to a "strong-buy" rating in a research note on Thursday, January 30th. Morgan Stanley began coverage on Roche in a report on Wednesday, February 12th. They set an "equal weight" rating on the stock. Finally, UBS Group raised shares of Roche from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, one has issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy".

Read Our Latest Analysis on Roche

Roche Trading Down 2.5 %

Roche stock traded down $1.06 during trading hours on Wednesday, hitting $42.00. 1,863,188 shares of the stock were exchanged, compared to its average volume of 3,002,713. Roche has a 12 month low of $29.20 and a 12 month high of $43.96. The business's 50-day moving average is $39.31 and its two-hundred day moving average is $38.48. The company has a debt-to-equity ratio of 0.86, a current ratio of 1.26 and a quick ratio of 0.97.

Institutional Investors Weigh In On Roche

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Brooklyn Investment Group acquired a new position in Roche in the third quarter worth $40,000. IHT Wealth Management LLC acquired a new position in Roche during the 3rd quarter worth about $236,000. Verity Asset Management Inc. increased its position in Roche by 26.8% in the 4th quarter. Verity Asset Management Inc. now owns 8,036 shares of the company's stock valued at $280,000 after acquiring an additional 1,697 shares in the last quarter. Canopy Partners LLC raised its stake in shares of Roche by 4.6% in the third quarter. Canopy Partners LLC now owns 7,772 shares of the company's stock worth $310,000 after acquiring an additional 344 shares during the last quarter. Finally, HighPoint Advisor Group LLC lifted its position in shares of Roche by 2.8% during the fourth quarter. HighPoint Advisor Group LLC now owns 11,091 shares of the company's stock worth $387,000 after purchasing an additional 304 shares in the last quarter.

About Roche

(Get Free Report)

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads

Should You Invest $1,000 in Roche Right Now?

Before you consider Roche, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roche wasn't on the list.

While Roche currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

3 AI Stocks to Watch After NVIDIA’s Dip

3 AI Stocks to Watch After NVIDIA’s Dip

NVIDIA may be down, but the AI boom isn’t slowing anytime soon! While investors react to short-term price swings, smart money is looking at three stocks that could benefit from NVIDIA’s continued domi

Recent Videos

Will Tesla’s Robot Future Save Its Falling Stock?
NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last
Best ETFs for Spring 2025: Strong and Steady Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads